Login to Your Account



NPS Takes $145M Advance on Sensipar Royalties from Amgen

By Catherine Shaffer


Wednesday, August 17, 2011
NPS Pharmaceuticals Inc. will receive a $145 million advance on royalties from Sensipar/Mimpara (cinacalcet HCL) sales from partner Amgen Inc. and will retire its 15.5 percent secured class B notes when they become redeemable Sept. 20. The move will save NPS about $13 million in interest expenses over the next two years.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription